SI4003989T1 - 6,7-dihidro-5H-pirido(2,3-c)piridazinski derivati in sorodne spojine kot inhibitorji Bcl-xL proteina in proapoptotična sredstva za zdravljenje raka - Google Patents
6,7-dihidro-5H-pirido(2,3-c)piridazinski derivati in sorodne spojine kot inhibitorji Bcl-xL proteina in proapoptotična sredstva za zdravljenje rakaInfo
- Publication number
- SI4003989T1 SI4003989T1 SI202030373T SI202030373T SI4003989T1 SI 4003989 T1 SI4003989 T1 SI 4003989T1 SI 202030373 T SI202030373 T SI 202030373T SI 202030373 T SI202030373 T SI 202030373T SI 4003989 T1 SI4003989 T1 SI 4003989T1
- Authority
- SI
- Slovenia
- Prior art keywords
- pyrido
- bcl
- dihydro
- pro
- treating cancer
- Prior art date
Links
- KJICBBFBFGDSMB-UHFFFAOYSA-N 5,6,7,8-tetrahydropyrido[2,3-c]pyridazine Chemical class N1=CC=C2CCCNC2=N1 KJICBBFBFGDSMB-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 102000055104 bcl-X Human genes 0.000 title 1
- 108700000711 bcl-X Proteins 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000000861 pro-apoptotic effect Effects 0.000 title 1
- 229940121649 protein inhibitor Drugs 0.000 title 1
- 239000012268 protein inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19188749 | 2019-07-29 | ||
EP20751092.6A EP4003989B1 (en) | 2019-07-29 | 2020-07-28 | 6,7-dihydro-5h-pyrido[2,3-c]pyridazine derivatives and related compounds as bcl-xl protein inhibitors and pro-apoptotic agents for treating cancer |
PCT/EP2020/071181 WO2021018858A1 (en) | 2019-07-29 | 2020-07-28 | 6,7-dihydro-5h-pyrido[2,3-c]pyridazine derivatives and related compounds as bcl-xl protein inhibitors and pro-apoptotic agents for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SI4003989T1 true SI4003989T1 (sl) | 2024-04-30 |
Family
ID=67514283
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI202030373T SI4003989T1 (sl) | 2019-07-29 | 2020-07-28 | 6,7-dihidro-5H-pirido(2,3-c)piridazinski derivati in sorodne spojine kot inhibitorji Bcl-xL proteina in proapoptotična sredstva za zdravljenje raka |
Country Status (28)
Country | Link |
---|---|
US (1) | US20220363677A1 (sl) |
EP (1) | EP4003989B1 (sl) |
JP (1) | JP2022542595A (sl) |
KR (1) | KR20220041132A (sl) |
CN (1) | CN114450284B (sl) |
AR (1) | AR119494A1 (sl) |
AU (1) | AU2020319652A1 (sl) |
BR (1) | BR112022001373A2 (sl) |
CA (1) | CA3148506A1 (sl) |
CL (1) | CL2022000102A1 (sl) |
CO (1) | CO2022000612A2 (sl) |
CR (1) | CR20220016A (sl) |
DK (1) | DK4003989T3 (sl) |
FI (1) | FI4003989T3 (sl) |
GE (1) | GEP20237581B (sl) |
IL (1) | IL289933A (sl) |
JO (1) | JOP20220010A1 (sl) |
LT (1) | LT4003989T (sl) |
MA (1) | MA56649B1 (sl) |
MX (1) | MX2022001191A (sl) |
PE (1) | PE20220705A1 (sl) |
PL (1) | PL4003989T3 (sl) |
PT (1) | PT4003989T (sl) |
RS (1) | RS65248B1 (sl) |
SI (1) | SI4003989T1 (sl) |
TW (1) | TWI751629B (sl) |
UY (1) | UY38810A (sl) |
WO (1) | WO2021018858A1 (sl) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7065951B2 (ja) | 2017-09-22 | 2022-05-12 | ジュビラント エピパッド エルエルシー | Pad阻害剤としての複素環式化合物 |
CA3076476A1 (en) | 2017-10-18 | 2019-04-25 | Jubilant Epipad LLC | Imidazo-pyridine compounds as pad inhibitors |
CA3080677A1 (en) | 2017-11-06 | 2019-05-09 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation |
MX2020005363A (es) | 2017-11-24 | 2020-10-01 | Jubilant Episcribe Llc | Compuestos heterociclicos como inhibidores de prmt5. |
MX2020009517A (es) | 2018-03-13 | 2021-01-20 | Jubilant Prodel LLC | Compuestos biciclicos como inhibidores de la interaccion/activacio n de pdl/pd-l1. |
WO2022115477A1 (en) * | 2020-11-24 | 2022-06-02 | Novartis Ag | Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
CA3206906A1 (en) * | 2021-02-02 | 2022-08-11 | Andras Herner | Selective bcl-xl protac compounds and methods of use |
CN114181039A (zh) * | 2021-12-23 | 2022-03-15 | 凯美克(上海)医药科技有限公司 | 一种4,4-二苯基-3-丁烯-1-醇的合成方法 |
WO2023225359A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
TW202404645A (zh) | 2022-05-20 | 2024-02-01 | 瑞士商諾華公司 | Met bcl-xl抑制劑抗體-藥物結合物及其使用方法 |
WO2023225320A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009335843A1 (en) * | 2008-12-19 | 2011-07-21 | Abbvie Inc. | Heterocyclic compounds and methods of use |
TWI571466B (zh) * | 2011-10-14 | 2017-02-21 | 艾伯維有限公司 | 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑 |
US8889675B2 (en) * | 2011-10-14 | 2014-11-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
TW201414737A (zh) * | 2012-07-13 | 2014-04-16 | 必治妥美雅史谷比公司 | 作爲激酶抑制劑之咪唑并三□甲腈 |
FR3015483B1 (fr) | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
EP3468615A1 (en) * | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-egfr antibody drug conjugates |
CN109422754A (zh) * | 2017-08-24 | 2019-03-05 | 上海迪诺医药科技有限公司 | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 |
-
2020
- 2020-07-27 AR ARP200102096A patent/AR119494A1/es unknown
- 2020-07-28 LT LTEPPCT/EP2020/071181T patent/LT4003989T/lt unknown
- 2020-07-28 WO PCT/EP2020/071181 patent/WO2021018858A1/en active Application Filing
- 2020-07-28 US US17/630,673 patent/US20220363677A1/en active Pending
- 2020-07-28 FI FIEP20751092.6T patent/FI4003989T3/fi active
- 2020-07-28 PL PL20751092.6T patent/PL4003989T3/pl unknown
- 2020-07-28 AU AU2020319652A patent/AU2020319652A1/en active Pending
- 2020-07-28 SI SI202030373T patent/SI4003989T1/sl unknown
- 2020-07-28 UY UY0001038810A patent/UY38810A/es unknown
- 2020-07-28 TW TW109125467A patent/TWI751629B/zh active
- 2020-07-28 MA MA56649A patent/MA56649B1/fr unknown
- 2020-07-28 CA CA3148506A patent/CA3148506A1/en active Pending
- 2020-07-28 PT PT207510926T patent/PT4003989T/pt unknown
- 2020-07-28 EP EP20751092.6A patent/EP4003989B1/en active Active
- 2020-07-28 JO JOP/2022/0010A patent/JOP20220010A1/ar unknown
- 2020-07-28 RS RS20240257A patent/RS65248B1/sr unknown
- 2020-07-28 CN CN202080068082.7A patent/CN114450284B/zh active Active
- 2020-07-28 DK DK20751092.6T patent/DK4003989T3/da active
- 2020-07-28 PE PE2022000174A patent/PE20220705A1/es unknown
- 2020-07-28 CR CR20220016A patent/CR20220016A/es unknown
- 2020-07-28 MX MX2022001191A patent/MX2022001191A/es unknown
- 2020-07-28 KR KR1020227005751A patent/KR20220041132A/ko active Search and Examination
- 2020-07-28 BR BR112022001373A patent/BR112022001373A2/pt unknown
- 2020-07-28 JP JP2022505554A patent/JP2022542595A/ja active Pending
- 2020-07-28 GE GEAP202015865A patent/GEP20237581B/en unknown
-
2022
- 2022-01-13 CL CL2022000102A patent/CL2022000102A1/es unknown
- 2022-01-17 IL IL289933A patent/IL289933A/en unknown
- 2022-01-25 CO CONC2022/0000612A patent/CO2022000612A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
UY38810A (es) | 2021-02-26 |
CL2022000102A1 (es) | 2022-11-04 |
PT4003989T (pt) | 2024-01-30 |
CN114450284A (zh) | 2022-05-06 |
EP4003989B1 (en) | 2023-12-27 |
CR20220016A (es) | 2022-03-02 |
KR20220041132A (ko) | 2022-03-31 |
TWI751629B (zh) | 2022-01-01 |
PL4003989T3 (pl) | 2024-04-29 |
PE20220705A1 (es) | 2022-05-04 |
TW202118764A (zh) | 2021-05-16 |
RS65248B1 (sr) | 2024-03-29 |
WO2021018858A1 (en) | 2021-02-04 |
AR119494A1 (es) | 2021-12-22 |
CO2022000612A2 (es) | 2022-01-28 |
BR112022001373A2 (pt) | 2022-06-07 |
JP2022542595A (ja) | 2022-10-05 |
EP4003989A1 (en) | 2022-06-01 |
FI4003989T3 (fi) | 2024-03-21 |
IL289933A (en) | 2022-03-01 |
CN114450284B (zh) | 2024-05-07 |
CA3148506A1 (en) | 2021-02-04 |
DK4003989T3 (da) | 2024-03-25 |
MA56649B1 (fr) | 2024-02-29 |
LT4003989T (lt) | 2024-02-12 |
MX2022001191A (es) | 2022-02-22 |
US20220363677A1 (en) | 2022-11-17 |
JOP20220010A1 (ar) | 2023-01-30 |
GEP20237581B (en) | 2023-12-25 |
AU2020319652A1 (en) | 2022-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI4003989T1 (sl) | 6,7-dihidro-5H-pirido(2,3-c)piridazinski derivati in sorodne spojine kot inhibitorji Bcl-xL proteina in proapoptotična sredstva za zdravljenje raka | |
EP3569601A3 (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
MY158932A (en) | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | |
EP3743069A4 (en) | DEGRADER OF BCL-2 PROTEIN FOR CANCER TREATMENT | |
NZ739893A (en) | Fused pyrimidine compound or salt thereof | |
MX2023000025A (es) | Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos. | |
SI3880676T1 (sl) | Derivati 2,3-dihidro-1h-pirolo(3,4-c)piridin-1-ona kot zaviralci hpk1 za zdravljenje raka | |
EP3983445A4 (en) | CANCER TREATMENT COMPOSITIONS AND METHODS | |
PH12020550457A1 (en) | Compounds and compositions for treating hematological disorders | |
EP2205088A4 (en) | NAPHTHALIN-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | |
IL290177A (en) | History of 4,2,1-oxadiazol-5-one for cancer therapy | |
MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
ZA202006071B (en) | Antiproliferation compounds and uses thereof | |
EP3965896A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | |
EP4003351A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
IL288953A (en) | Pharmaceutical compounds, kits and methods for the treatment of cancerous tumors | |
MX2020011826A (es) | Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas. | |
EP3983014A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | |
EP3781148A4 (en) | THERAPEUTIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER WITH 6,8-BIS-BENZYLTHIO-OCTONIC ACID | |
MX2023005530A (es) | Metodos y composiciones que comprenden un inhibidor de krasg12c y un antagonista de union a pd-l1 para tratar cancer de pulmon. | |
EP3897607A4 (en) | COMPOSITIONS AND METHODS OF THERAPY FOR TREATING CANCER USING 6,8-BIS-BENZYLTHIO-OCTANOIC ACID AND AN AUTOPHAGY INHIBITOR | |
EP3962896A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | |
KR102276379B9 (ko) | IF1 (ATPase inhibitory factor 1)을 유효성분으로 함유하는 골질환의 예방 또는 치료용 약학 조성물 | |
EP3930705A4 (en) | METHODS AND COMPOSITIONS FOR TREATING CANCER | |
EP3826629A4 (en) | METHODS AND THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF PANCREATIC CANCER USING 6,8-BIS(BENZYLSULFANYL)OCTANOIC ACID |